David Young - Jan 1, 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Pres. Research & Development, Director
Signature
/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Jan 1, 2024
Transactions value $
-$1,445
Form type
4
Date filed
4/12/2024, 05:01 PM
Previous filing
Oct 12, 2023
Next filing
Feb 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Options Exercise +1.68K +2.11% 81.1K Jan 1, 2024 Direct F1, F2
transaction PCSA Common Stock Tax liability -$1.45K -518 -0.64% $2.79 80.5K Jan 1, 2024 Direct F2
holding PCSA Common Stock 31K Jan 1, 2024 By Young-Plaisance Revocable Trust F2
holding PCSA Common Stock 10.8K Jan 1, 2024 By Family Entities F2
holding PCSA Common Stock 18.5K Jan 1, 2024 By CorLyst, LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Options Exercise $0 -1.68K -7.97% $0.00 19.3K Jan 1, 2024 Common Stock 1.68K $0.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Distribution of vested restricted shares.
F2 Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.